ASX:PTX Prescient Therapeutics (PTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Prescient Therapeutics Stock (ASX:PTX) 30 days 90 days 365 days Advanced Chart Get Prescient Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume537,831 shsAverage VolumeN/AMarket CapitalizationA$38.66 millionP/E RatioN/ADividend Yield5.88%Price TargetN/AConsensus RatingN/A Company Overview Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia. Read More Receive PTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prescient Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTX Stock News HeadlinesVital Signs Podcast: Why this clinical-stage oncology company is “first in class”July 2, 2025 | msn.comPrescient advances new therapies for hard-to-treat cancersJune 27, 2025 | msn.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 7 at 2:00 AM | Crypto 101 Media (Ad)Prescient Therapeutics CEO highlights PTX-100 progress in RAS-Driven cancer trialJune 25, 2025 | msn.comPrescient doses first patient in Phase 2a cancer trialMay 30, 2025 | msn.comPrescient Therapeutics Advances with Phase 2A Trial of PTX-100May 28, 2025 | tipranks.comPrescient Therapeutics Highlights Forward-Looking Risks in Cancer Therapy DevelopmentMay 20, 2025 | tipranks.comPrescient Therapeutics Director Increases StakeMay 6, 2025 | tipranks.comSee More Headlines PTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Prescient Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prescient Therapeutics investors own include NOVONIX (NVX), SkyCity Entertainment Group (SKC), KLA (KLAC), Findi (FND) and Chalice Mining (CHN). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PTX CIKN/A Webwww.ptxtherapeutics.com Phone61 3 9692 7222FaxN/AEmployees171Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$8.24 million Net Margins-221.91% Pretax MarginN/A Return on Equity-40.50% Return on Assets-18.52% Debt Debt-to-Equity Ratio1.83 Current Ratio8.08 Quick Ratio17.31 Sales & Book Value Annual SalesA$3.71 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.91 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares805,320,000Free FloatN/AMarket CapA$38.66 million OptionableNot Optionable Beta1.19 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ASX:PTX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prescient Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Prescient Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.